<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Objective: High-mobility group box 1 (HMGB1), an active receptor for advanced glycation endproducts (RAGE), functions as a potent proinflammatory cytokine-like factor that contributes to the pathogenesis of vasculature </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo> (DM) is associated with accelerated development of both microvascular and macrovascular disease and increases the risk of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Using a model of <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced type-1 <z:mp ids='MP_0002055'>diabetes</z:mp> (T1DM) in rats, we investigated the changes in HMGB and RAGE and tested the effects of Niaspan, a slow release form of niacin, on the expression of pro-inflammatory proteins in rats after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Research design and methods: T1DM rats were subjected to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) and treated without or with Niaspan (40 mg/kg) daily for 14 days after MCAo </plain></SENT>
<SENT sid="4" pm="."><plain>Non-<z:chebi fb="1" ids="9288">streptozotocin</z:chebi> rats (WT) were also subjected to MCAo </plain></SENT>
<SENT sid="5" pm="."><plain>Immunostaining for <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> including HMGB1, RAGE, matrix metalloproteinase-9 (MMP-9) and toll-like receptor 4 (TLR4) immunostaining (n=8/group) and Western blotting (n=4/group) were performed </plain></SENT>
<SENT sid="6" pm="."><plain>Results: Compared to WT-MCAo rats, T1DM-MCAo rats showed an increased expression of HMGB1 (0.82±0.07 vs. 1.81±0.98, P&lt;0.05), RAGE (1.31±0.22 vs. 3.77±0.72, P&lt;0.05), MMP-9 (0.74±0.08 vs. 1.61±0.09, P&lt;0.05) and TLR4 (2.85±0.22 vs. 6.72±0.44, P&lt;0.05) after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Niaspan treatment significantly attenuated the expression of HMGB1 (1.80±0.98 vs. 1.31±0.01, P&lt;0.05), RAGE (3.77±0.71 vs. 1.78±0.45, P&lt;0.05), MMP-9 (1.61±0.09 vs. 0.97±0.07, P&lt;0.05) and TLR4 (6.72±0.44 vs. 2.28±0.43, P&lt;0.05) in the ischemic brain in T1DM-MCAo rats </plain></SENT>
<SENT sid="8" pm="."><plain>Conclusions: T1DM increases HMGB1/RAGE, TLR4 and MMP-9 expression after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Niaspan treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> in T1DM rats inhibits HMGB1/RAGE, TLR4 and MMP-9 expression which may contribute to the <z:mp ids='MP_0001876'>reduced inflammatory response</z:mp> after <z:hpo ids='HP_0001297'>stroke</z:hpo> in T1DM rats </plain></SENT>
</text></document>